Photo taken from Drew Moghanaki/X
Jan 28, 2024, 15:04
Drew Moghanaki: RECIST over-classified ‘progression’ in 81% of cases without progression.
Drew Moghanaki, Chief of Thoracic Oncology in the UCLA Department of Radiation Oncology, shared a post on X/Twitter:
“This study evaluating the accuracy of RECIST for LC monitoring after SBRT for stage I (85%) or metastatic (15%) NSCLC demonstrated a PPV of only 0.16.
RECIST over-classified ‘progression’ in 81% of cases without progression (47/58)”
Source: Drew Moghanaki/X